1. Department of Pharmacology, Harold C. Simmons Comprehensive Cancer Center;
Theranostics. 2011 Apr 24;1:263-73. doi: 10.7150/thno/v01p0263.
Nanoparticulate imaging probes have become an increasingly important arsenal in the visualization of molecular markers for early diagnosis and post-therapy assessment of diseases. Surface functionalization of these nanoparticles has led to the development of a variety of targeted nanoprobes for various imaging modalities (e.g. PET, MRI, optical). Despite these advances, detailed understanding of the nanoparticle targeting kinetics, particularly at the early time points immediately after injection, is still lacking. In this study, we report the combination of a T(2)*-weighted time-resolved-MRI (TR-MRI) method with ultra-sensitive superparamagnetic polymeric micelle (SPPM) nanoprobes to quantify the targeting kinetics of cyclic (RGDfK) (cRGD)-encoded SPPM to angiogenic endothelium in subcutaneous human tumor xenograft models in mice. TR-MRI analyses of the α(v)β(3)-targeted and non-targeted SPPMs allowed for the subtraction of blood volume and extravascular signal components from the cRGD-SPPM data, resulting in a specific measurement of the accumulation kinetics of nanoprobes in lung, breast and brain cancer preclinical models. In all three models, α(v)β(3)-specific accumulation of SPPM nanoprobes was observed in the first 5 mins after intravenous injection (first order rate constants were in the range of 0.22-0.24 min(-1)). Similar α(v)β(3)-targeting kinetics was observed for cRGD-SPPM nanoprobes in different tumor xenograft models, consistent with the targeting of mouse angiogenic endothelium despite tumor inoculation from different human cancer cell lines. Results from this study offer new opportunities in the quantitative characterization of the targeting kinetics of cancer-specific nanoparticles to their intended biological targets in an intact animal, which provides fundamental insights on molecular recognition processes in vivo for further development of these nanoprobes.
纳米颗粒成像探针已成为可视化疾病早期诊断和治疗后评估的分子标志物的重要武器。这些纳米颗粒的表面功能化导致了各种靶向纳米探针的发展,用于各种成像方式(例如 PET、MRI、光学)。尽管取得了这些进展,但对纳米颗粒靶向动力学的详细了解,特别是在注射后立即的早期时间点,仍然缺乏。在这项研究中,我们报告了 T(2)*-加权时间分辨 MRI (TR-MRI)方法与超灵敏超顺磁聚合物胶束 (SPPM)纳米探针的结合,以定量测量环状 (RGDfK) (cRGD) 编码的 SPPM 对皮下人肿瘤异种移植模型中血管生成内皮的靶向动力学在小鼠中。靶向和非靶向 SPPM 的 TR-MRI 分析允许从 cRGD-SPPM 数据中减去血容量和血管外信号成分,从而对肺癌、乳腺癌和脑癌临床前模型中纳米探针的积累动力学进行特异性测量。在所有三种模型中,在静脉注射后 5 分钟内观察到 SPPM 纳米探针的α(v)β(3)-特异性积累(一级速率常数范围在 0.22-0.24 min(-1))。在不同的肿瘤异种移植模型中,cRGD-SPPM 纳米探针也观察到类似的α(v)β(3)-靶向动力学,尽管接种的是来自不同人癌细胞系的肿瘤,但靶向的是小鼠血管生成内皮。这项研究的结果为在完整动物中对癌症特异性纳米颗粒对其预期生物靶标的靶向动力学进行定量表征提供了新的机会,为进一步开发这些纳米探针提供了体内分子识别过程的基本见解。